The Pharmaceutical Benefits Advisory Committee (PBAC)
has recently opened a period of consumer comments on Dulaglutide
(Trulicity) and is interested in hearing from people living with
type 2 diabetes, their family, friends and carers, healthcare
professionals and patient or consumer groups about...
16 September 2019
/
Latest News
/
Government & policy, Staying well
More